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Abstract
Background: Ethical approval (EA) must be obtained before medical research can start. We describe the differences
in EA for an pseudonymous, non-interventional, observational European study.
Methods: Sixteen European national coordinators (NCs) of the international study on very old intensive care
patients answered an online questionnaire concerning their experience getting EA.
Results: N = 8/16 of the NCs could apply at one single national ethical committee (EC), while the others had to
apply to various regional ECs and/or individual hospital institutional research boards (IRBs). The time between
applying for EA and the first decision varied between 7 days and 300 days. In 9/16 informed consent from the
patient was not deemed necessary; in 7/16 informed consent was required from the patient or relatives. The
upload of coded data to a central database required additional information in 14/16. In 4/16 the NCs had to ask
separate approval to keep a subject identification code list to de-pseudonymize the patients if questions would
occur. Only 2/16 of the NCs agreed that informed consent was necessary for this observational study. Overall, 6/16
of the NCs were satisfied with the entire process and 8/16 were (very) unsatisfied. 11/16 would welcome a
European central EC that would judge observational studies for all European countries.
Discussion: Variations in the process and prolonged time needed to get EA for observational studies hampers
inclusion of patients in some European countries. This might have a negative influence on the external validity.
Further harmonization of ethical approval process across Europe is welcomed for low-risk observational studies.
Conclusion: Getting ethical approval for low-risk, non-interventional, observational studies varies enormously across
European countries.
Background
When doing medical research there is a potential dispar-
ity between the interests of the researcher and the pa-
tient who is going to be subjected to the medical
research. For this reason, medical ethical approval has to
be obtained before research can be started. The medical
ethical committees (ECs) or institutional review boards
(IRBs) should weight the benefits of medical research
against the potential harms for the patient. Interven-
tional trials should only commence if, at least, the min-
imal legal, judicial and ethical standards are met. The
European Union (EU) has issued a clinical trials directive
(EU-CTD1) in 2001, which was implemented in the
member states in 2004 [1]. Since then, more than 10
years have passed and a new clinical trials regulation has
now been implemented (EU-CTD2) [2]. In this process,
all countries have streamlined the process of getting ap-
proval for medical research and have appointed national
medical ethical committees for the analyses and approval
of medical research. This is especially well regulated for
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studies with an intervention, like (randomized) interven-
tional trials.
However, observational research is generally consid-
ered as having a minimal risk for the participants. In
many countries regulations have been developed to ei-
ther exempt these studies from ethical review or provide
the option of proportional review. These types of review
are often delegated to the chair or smaller group of the
ethical committee as they do not usually require a full
board review [3]. However, up to date most of the re-
search on timeliness of the ethical review has focused on
those traditional interventional trials that require full re-
view. We recently performed a multinational, observa-
tional study of very old critically ill patients (the VIP1-
study) [4]. The goal of the VIP1-study was to analyze
whether frailty was associated with poor outcome in this
elderly patient group. Performing this research provided
us with an opportunity to explore how differently ethical
approval processes are working in various countries. The
VIP1-study is prototypical for low-risk observational re-
search. In short, in this study we included 5021 patients
over 80 years old from 311 ICUs. We looked at reasons
for admission, severity of disease, frailty, treatments dur-
ing ICU (e.g. mechanical ventilation, renal replacement
therapy, and vasopressor treatment), limitations in life
sustaining therapy and outcome at 30 days. The data was
collected in central online database and apart from age,
gender and study number no other data was collected
that could lead to identification of the patients. National
Coordinators (NCs) were to apply for national ethical
approval at the appropriate EC. We aimed for a waiver
of informed consent but various countries demanded
written informed consent prior to inclusion. For a more
detailed description of the methods and definitions we
refer to the publication of the VIP1-study [4].
Here, we describe the differences in the processes to
obtain ethical clearance in the participating European
and EU affiliated countries and the opinions of the Na-
tional Coordinators about the medical ethical approval
process.
Methods
Originally, it was planned to get ethical approval from
the participating countries in the first 6 months of 2016.
The first center in Europe to apply for ethical approval
for the VIP1-study started in May 2016. The last
country started with this procedure in October 2016.
Each country had a designated National Coordinator
(NC), who was responsible for the process of getting
national ethical approval. In February 2017 an online
questionnaire concerning the experience of getting
ethical approval with 11 questions was sent out to 16
European NCs (Table 1).
Definitions
Every country has its own procedure to judge medical
research protocols. We defined a “national medical eth-
ical committee” as a committee that has the authority to
judge an application for the entire country. A “regional
medical ethical committee” has the authority to judge a
medical research protocol for a particular region or state
but not for the entire country. In many countries a local
hospital ethical committee has to judge the medical re-
search protocol as well. Their judgement can only be
used as approval for that particular institute. We defined
them as “institutional research boards” (IRBs).
Ethical clearance
The Regional Committee for Medical and Health Re-
search Ethics, Western-Norway was asked to judge
whether sending out a questionnaire on the ethical
process to the NCs needed ethical committee review.
They judged that sending out such a questionnaire was
exempted from ethical review.
Results
Half of the countries (n = 8/16) needed apply to only
one national medical ethical committee (national EC),
while the others had to apply to the national ECs and
subsequently to the individual hospital institutional re-
search boards (IRBs) (question 1).
The most frequent body to be approached (question 2)
was a local hospital institution review board (IRB) (67%),
followed by a regional EC (33%) and a national EC (25%)
. In one country all participating hospitals had to send
individual applications to their respective IRBs since
there was no national medical ethical committee. Most
hospitals had to provide more specific information re-
garding the upload of data (question 5) to a central data-
base abroad (n = 14/16). One country had to apply for
this at a separate EC, because the national EC was not
allowed to judge data collection in a foreign country. In
n = 4/16 the NCs had to ask additional ethical approval
to keep a local subject identification code list to de-
pseudonymize the patients to be able to answer queries
from the coordinating center (question 6). In 11 coun-
tries this was not necessary and in one country there
was a separate application for this, resulting in two sep-
arate ethical approval rounds to the central EC.
The time from application until the first national ap-
proval (question 3) is shown in Fig. 1. The time-to-
approval ranged from less than a week to more than
300 days.
In n = 9/16 informed consent from the patient was not
deemed necessary (question 4), and in n = 7/16 informed
consent was prospectively required from the patient or
the relatives or retrospectively from the patient. In 5
countries consent from the patients was necessary in
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advance, and in one country survivors had to consent in
retrospect and only then was it allowed to use their data.
One country allowed for consent by the family (proxy)
without confronting the patient. Only n = 2/16 of the
NCs agreed that informed consent was necessary for
such an observational study (question 8).
Overall, n = 6/16 of the NCs were satisfied with the
entire process of ethical approval, n = 8/16 were (very)
unsatisfied with the process and n = 2/16 were neutral
(time consuming but necessary) (question 9)(Fig. 2).
However, there was no clear correlation between the
time-to-approval and being dissatisfied (p = 0.622). N =
11/16 would welcome a European central EC that would
judge observational studies for all European countries,
while n = 5/16 were “not sure” fearing “more bureau-
cracy” in the ethical approval process (question 10).
Discussion
International observational studies of consecutive pa-
tients can reveal important differences in admission pol-
icies, treatments and outcomes of certain subgroups of
ICU patients. Such observational studies often collect
pseudo-anonimized or coded patient information and no
particular treatment or intervention is imposed upon the
subjects of the study. The potential harm to the subjects
is, therefore, negligible and most would claim none. One
could assume that these observational studies are
assessed by the national ethical committees in an identi-
cal swift modus and the need for informed consent is
waived. On the contrary, here we describe that this
process went from smooth to such a prolonged period
that one country could not even enter the study before
the proposed end date [5].
Table 1 The questionnaire to the national coordinators
Question Answer possibilities
Q1 Did you have to apply to more than one body in order to get approval for the study? … yes
… no
… other, please specify
Q2 If Yes on Q1: Which bodies (committees) did you apply for consent? … a national committee/body
… a regional committee/body
… a local hospital intitutional research board
… other, please specify
Q3 How long was the application process from start to decision (weeks)? …. weeks
Q4 Did you have to get informed consent for this study? … yes, from the patient
… yes, from the family
… yes, but in retrospect from the patient
… No, not deemed necessary
Q5 Is there a specific regulation when you send data electronically to a common
database in another country?
… no
… yes, it must be specified in detail on the application
… yes, there is a seperate body and an independent
application
Q6 Did you have to seek allowance to have your own (local) file/database with names
of the included patients from your unit?
… yes
… no
… never thought of it
Q7 If YES from patient or family on Q4, how often was consent denied? … never
… occasionally
… sometimes
… frequently
Q8 Do you consider (personal opinion) it necessary to have informed consent for such a
study?
… yes
… no
… uncertain
… other, please specify
Q9 All in all: How satisfied are you with the ethical clearance process for this study? … very satisfied
… satisfied
… neutral
… unsatisfied
… very unsatisfied
… other, please specify
Q10 What is your opinion of having a common EU regulation on research ethics, and that
acceptance in one country will bind the rest (similar to drug-approval regulations)
… I am in favour of this
… I am not sure
… I am against this
… Other, please specify
Q11 The name of your country …
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In this survey, covering 16 European countries, we
have demonstrated that there is very large variety of the
ethical processes and outcome from either national ECs’,
regional ECs’ or IRBs’ approval with regard to an identi-
cal study protocol. In most countries, more than one
level of ethical approval had to be approached. Often a
national EC needed to assess the research protocol and,
once approved, the local IRBs needed to consent with
the protocol as well. The time from applications to deci-
sion was unexpectedly large and only a few countries re-
ceived feedback within a month from their national EC
[6–8]. After a national EC has cleared the study local
IRBs need to assess whether the study can be performed
at their institution. Sometimes local IRBs are stricter
than their national ECs and sometimes these IRBs
needed additional information that was lacking from the
original study protocol. Clearly, the differences in
“approval time” are not solely the responsibility of the
ethical committees. Sometimes insufficient information
in the protocol is reason for additional queries. This will
lead to additional delay and the majority of ICUs needed
additional time between start of the national EC proced-
ure and the final local IRB approval [9]. Moreover, after
this study was performed most of the European coun-
tries that have participated in our research have imple-
mented the new General Data Protection Regulation
(GDPR) which has had a major impact on the collection
of observational data [10].
Another major disparity between countries was the
need for informed consent. A basic requisite for medical
research is that every patient has the right to decide
whether or not he/she will participate in medical re-
search. However, if the patient is unable to consent be-
cause of severe illness informed consent could be asked
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retrospectively. However, some patients might not be
able to give informed consent afterwards (because they
are deceased or cognitively impaired). Leaving these pa-
tients out of the analyses might hamper the external val-
idation of the research. In such cases the researchers can
apply for a waiver of informed consent to the EC. The
EC can grant such a waiver provided that the research
poses important societal value and the research poses no
more than minimal risk to the participants. We think
this applies to observational studies in critically ill, eld-
erly patients. The majority of countries were allowed to
perform this study without any informed consent from
the patient, but in a substantial amount of countries
such permission had to be sought before inclusion of the
patient [11]. If a patient is, for medical reasons, not able
to consent (e.g. unconscious, sedated, etc.) and subse-
quently dies, this will create potential loss in patient re-
cruitment subsequently leading to a selection bias and
this may diminish the validity of the study [12]. A poten-
tial solution is to accept that survivors may claim their
data to be removed (retrospective consent) but allow in-
clusion of data from deceased patients, despite the bias
that also this option can introduce on the final results
[13, 14]. However, only one country used this method
and from the 226 included patients only one patient
opted for removal of his data. The majority of national
coordinators (n = 14/16) judged this observational study
as having such a low potential of harm to the subjects
that they would not need informed consent for this
study. However, this leaves n = 2/16 that are convinced
that consent is necessary even for anonymous observa-
tional registries.
Half of the national coordinators were not satisfied
with the process. There was no obvious concordance be-
tween the time needed to get the study approved by the
national EC and satisfaction. However, the countries in
which the verdict was received swiftly were invariably
satisfied with the entire process. Clearly a swift approval
process leads to higher satisfaction. Especially in coun-
tries with a very prolonged EC process the national co-
ordinators were dissatisfied and more willing to accept a
centralized European ethical clearance entity for non-
interventional studies/registries. At present, a new clin-
ical trials directive (EU-CTD2) is being implemented.
However, this directive particularly focuses on interven-
tional trials (that, indeed, have a high potential risk of
harm for the medical subjects). This leaves a gap in
international legislation for pseudo-anonymous observa-
tional registries. The majority of the national coordina-
tors would welcome a central European ethical
organization for observational studies which would
speed up national and local approvals. The general con-
sensus was that such a non-interventional study should
not take prolonged periods to be approved.
We have learned that we need to allow for up to one
year to get all the countries to approve such a study [15,
16]. Not incorporating this “waiting time” in study pro-
tocols will lead to loss of countries and will, therefore,
diminish the external validity of the findings for the
European population. We presume more delay in ap-
proval for studies with a higher potential of harm for pa-
tients (like interventional studies or even patient
questionnaires) [17, 18].
Obviously, this analysis has limitations. We only asked
the national coordinators of the VIP1-study to provide
us with their ethical approval experiences. After the na-
tional coordinators had gained ethical clearance many
local researchers needed to go through a similar experi-
ence at their local IRBs. A swift approval at a national
level may not be followed by a similarly swift approval at
a local level, or vice versa. Such data were not incorpo-
rated in this analysis. Obviously, the results from our
study are not necessarily transferrable to other studies
(limited external validity).
Conclusion
We conclude that further harmonization between Euro-
pean countries in ethical clearance for observational,
non-interventional studies and registries is desirable.
However, these differences between European countries
need to be considered and incorporated in the research
plan in order to prevent missing important contributors.
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